A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Leaf Vertical Inc.160 enrolled

Overview

A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI Malignancies

Several studies have shown a potential anti-tumor role for cannabinoids by modulating cell signaling pathways, inhibiting angiogenesis, inducing apoptosis, and overcoming chemotherapy resistance. In phase I trials, cannabinoids have been shown to enhance the uptake of chemotherapy into malignant cells without affecting normal cells. The investigators seeks to demonstrate that the combination of chemotherapy with BRCX014 will have a greater anti-tumor and anti-proliferative activity when compared to standard of care alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

160

Conditions

Cancer of Pancreas Cancer of Liver Cancer of Rectum Cancer of Colon

Interventions

CannabidiolDRUG

* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day * Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal

BortezomibDRUG

Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.

LeucovorinDRUG

Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.

5-FUDRUG

OxaliplatinDRUG

BevacizumabDRUG

IrinotecanDRUG

GemcitabineDRUG

Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.

TemozolomideDRUG

Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed and dated informed consent 2. Male and Females age 18 to 80 years old at the time of screening 3. Confirmed tissue diagnosis of Multiple myeloma, GI malignancy by a licensed pathologist 4. A performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale. 5. Females of childbearing potential willing to utilize two approved forms of contraceptives (e.g., birth control, abstinence, spermicidal lube, intrauterine device \[IUD\]) 6. Male study subjects must be willing to use two approved forms of contraceptives (e.g., physical barrier-condoms, abstinence, spermicidal lube) Exclusion Criteria: 1. Subject is pregnant or plans to become pregnant or actively lactating/nursing 2. Hypersensitivity to any ingredient in the study product 3. Initial laboratory values as determined by the principal investigator to be clinically significant 4. A substance abuse history within the last five years 5. Any diseases or conditions that may interfere with the conduct of the study or interpretation of the study results 6. .Close affiliation with the investigational site (e.g., a close relative of the investigator), dependent person (employee or student of investigational site, or sponsor's staff) 7. Currently enrolled in another investigational clinical study 8. A known history of severe depression or psychiatric disorders or active suicidal ideation 9. Inability or unwillingness to cooperate with the study procedures for any reasons

Outcomes

Primary Outcomes

Response rate

The primary objective of this study is to evaluate the overall response rates of cancer patients as assessed by standard criteria.